APA (7th ed.) Citation

EC, K., AF, K., JT, S., H, T., Y, H., LS, T., . . . EK, C. (2004). Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis & Rheumatism, 50(5), 1400. https://doi.org/10.1002/art.20217

Chicago Style (17th ed.) Citation

EC, Keystone, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, and Chartash EK. "Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-controlled, 52-week Trial." Arthritis & Rheumatism 50, no. 5 (2004): 1400. https://doi.org/10.1002/art.20217.

MLA (9th ed.) Citation

EC, Keystone, et al. "Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-controlled, 52-week Trial." Arthritis & Rheumatism, vol. 50, no. 5, 2004, p. 1400, https://doi.org/10.1002/art.20217.